-
-
Depression and pregnancy, new vaccine recommendations from the CDC, cortico-steroids and/or antivirals for Bell's palsy, rasagiline and Parkinson's disease, and FDA Actions.
-
In a delayed-start trial of rasagiline in early Parkinson's disease, 1 mg rasagiline daily met all three predetermined endpoints consistent with disease modification. However, a dose of 2 mg daily did not meet all endpoints, complicating interpretation.
-
An oral direct thrombin inhibitor, dabigatran, prevents ischemic strokes in patients with atrial fibrillation, with fewer hemorrhagic strokes as compared to warfarin.
-
This open label trial reports on the long-term efficacy and tolerability of levetiracetam in children with late onset childhood occipital epilepsy.
-
In preliminary, open-label trials, rituximab shows promise as a treatment for IgM-associated neuropathy.
-
Transcranial magnetic stimulation was shown to have benefit during stroke rehabilitation therapy, in this randomized, controlled clinical trial.
-
Elevated levels of a specific organochlorine pesticide are associated with Parkinson's disease.
-
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis has been recognized in children as young as 23 months as well as adolescents.
-
Biomarkers in the cerebrospinal fluid may help in the early diagnosis of Alzheimer's disease.
